{"links": [{"source": 0, "target": "t8553", "value": "None"}, {"source": 0, "target": "t8540", "value": "None"}, {"source": 0, "target": "t8545", "value": "None"}, {"source": "t8553", "target": "t8560", "value": "None"}, {"source": "t8553", "target": "t8561", "value": "None"}, {"source": "t8553", "target": "t8554", "value": "None"}, {"source": "t8553", "target": "t8562", "value": "None"}, {"source": "t8553", "target": "t8556", "value": "None"}, {"source": "t8540", "target": "t8542", "value": "None"}, {"source": "t8540", "target": "t8541", "value": "None"}, {"source": "t8545", "target": "t8546", "value": "None"}, {"source": "t8554", "target": "t8555", "value": "None"}, {"source": "t8556", "target": "t8557", "value": "None"}, {"source": "t8542", "target": "t8543", "value": "None"}, {"source": "t8541", "target": "t8543", "value": "None"}, {"source": "t8546", "target": "t8548", "value": "None"}, {"source": "t8546", "target": "t8547", "value": "None"}, {"source": "t8546", "target": "d140", "value": "None"}, {"source": "t8546", "target": "d145", "value": "None"}, {"source": "t8546", "target": "d142", "value": "None"}, {"source": "t8546", "target": "d37", "value": "None"}, {"source": "t8546", "target": "d144", "value": "None"}, {"source": "t8555", "target": "d130", "value": "None"}, {"source": "t8557", "target": "t8558", "value": "None"}, {"source": "t8543", "target": "t8544", "value": "None"}, {"source": "t8543", "target": "d46", "value": "None"}, {"source": "t8548", "target": "t8549", "value": "None"}, {"source": "t8548", "target": "t8552", "value": "None"}, {"source": "t8547", "target": "t8551", "value": "None"}, {"source": "t8558", "target": "t8559", "value": "None"}, {"source": "t8549", "target": "t8550", "value": "None"}, {"source": "t8549", "target": "d130", "value": "None"}, {"source": "t8550", "target": "t8551", "value": "None"}], "nodes": [{"category": "disease", "id": 0, "name": "Pneumonia", "x": "250", "y": "350", "fixed": "true", "draggable": "true", "value": {"name": "Pneumonia"}}, {"category": "treatment", "id": "t8553", "name": "adult with lower respiratory tract infection", "draggable": "true", "value": {"name": "adult with lower respiratory tract infection", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:adult with lower respiratory tract infection", "drug": {}}}, {"category": "treatment", "id": "t8540", "name": "adult with community acquired pneumonia", "draggable": "true", "value": {"name": "adult with community acquired pneumonia", "type": "treatment related", "time": "", "intention": "", "description": "title:adult with community-acquired pneumonia", "drug": {}}}, {"category": "treatment", "id": "t8545", "name": "adult with diagnosed community acquired pneumonia", "draggable": "true", "value": {"name": "adult with diagnosed community acquired pneumonia", "type": "treatment related", "time": "", "intention": "", "description": "title:adult with diagnosed community-acquired pneumonia", "drug": {}}}, {"category": "treatment", "id": "t8560", "name": "service organisation", "draggable": "true", "value": {"name": "service organisation", "type": "treatment related", "time": "", "intention": "", "description": "title:service organisationhead:Service organisationPut in place processes to allow diagnosis (including X-rays) and treatment of community-acquired pneumonia within 4 hours of presentation to hospital.Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.3Chest X-ray and diagnosis within 4 hours of hospital presentation5Antibiotic therapy within 4 hours in hospitalSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191", "drug": {}}}, {"category": "treatment", "id": "t8561", "name": "antimicrobial stewardship", "draggable": "true", "value": {"name": "antimicrobial stewardship", "type": "treatment related", "time": "", "intention": "", "description": "title:antimicrobial stewardship", "drug": {}}}, {"category": "treatment", "id": "t8554", "name": "hospital acquired pneumonia", "draggable": "true", "value": {"name": "hospital acquired pneumonia", "type": "treatment related", "time": "", "intention": "", "description": "title:hospital-acquired pneumonia", "drug": {}}}, {"category": "treatment", "id": "t8562", "name": "patient experience in adult nhs services", "draggable": "true", "value": {"name": "patient experience in adult nhs services", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience in adult nhs services", "drug": {}}}, {"category": "treatment", "id": "t8556", "name": "tests in primary care", "draggable": "true", "value": {"name": "tests in primary care", "type": "treatment related", "time": "", "intention": "", "description": "title:tests in primary carehead:Tests in primary careFor people presenting with symptoms of lower respiratory tract infection in primary care, consider a point of care C-reactive protein test if after clinical assessment a diagnosis of pneumonia has not been made and it is not clear whether antibiotics should be prescribed. Use the results of the C-reactive protein test to guide antibiotic prescribing in people without a clinical diagnosis of pneumonia as follows: Do not routinely offer antibiotic therapy if the C-reactive protein concentration is less than 20 mg/litre. Consider a delayed antibiotic prescription (a prescription for use at a later date if symptoms worsen) if the C-reactive protein concentration is between 20 mg/litre and 100 mg/litre. Offer antibiotic therapy if the C-reactive protein concentration is greater than 100 mg/litre.NICE has published medtech innovation briefings on:  FebriDx for C-reactive protein and Myxovirus resistance protein A testing in primary careAlere Afinion CRP for C-reactive protein testing in primary careQuikRead go for C-reactive protein testing in primary care.See what NICE says on self-limiting respiratory tract and ear infections \u2013 antibiotic prescribing.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191", "drug": {}}}, {"category": "treatment", "id": "t8542", "name": "severity assessment in hospital", "draggable": "true", "value": {"name": "severity assessment in hospital", "type": "treatment related", "time": "", "intention": "", "description": "title:severity assessment in hospitalhead:Severity assessment in hospitalFor a definition, see severity assessment.When a diagnosis of community-acquired pneumonia is made at presentation to hospital, determine whether patients are at low, intermediate or high risk of death using the CURB65 score (see below).Use clinical judgement in conjunction with the CURB65 score to guide the management of community-acquired pneumonia, as follows: consider home-based care for patients with a CURB65 score of 0 or 1 consider hospital-based care for patients with a CURB65 score of 2 or more consider intensive care assessment for patients with a CURB65 score of 3 or more.Stratify patients presenting with community-acquired pneumonia into those with low-, moderate- or high-severity disease. The grade of severity will usually correspond to the risk of death.subhead:CURB65 score for mortality risk assessment in hospitalCURB65 score is calculated by giving 1 point for each of the following prognostic features: confusion (abbreviated Mental Test score 8 or less, or new disorientation in person, place or time; for guidance on delirium, see what NICE says on delirium) raised blood urea nitrogen (over 7 mmol/litre) raised respiratory rate (30 breaths per minute or more) low blood pressure (diastolic 60 mmHg or less, or systolic less than 90 mmHg) age 65 years or more.Patients are stratified for risk of death as follows:  0 or 1: low risk (less than 3% mortality risk) 2: intermediate risk (3\u201315% mortality risk) 3 to 5: high risk (more than 15% mortality risk).Score information from defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study (Lim WS, van der Eerden MM, Laing R, et al. 2003).Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.4Mortality risk assessment in hospital using CURB65 scoreSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191", "drug": {}}}, {"category": "treatment", "id": "t8541", "name": "severity assessment in primary care", "draggable": "true", "value": {"name": "severity assessment in primary care", "type": "treatment related", "time": "", "intention": "", "description": "title:severity assessment in primary carehead:Severity assessment in primary careFor a definition, see severity assessment.When a clinical diagnosis of community-acquired pneumonia is made in primary care, determine whether patients are at low, intermediate or high risk of death using the CRB65 score (see below). Use clinical judgement in conjunction with the CRB65 score to inform decisions about whether patients need hospital assessment as follows: consider home-based care for patients with a CRB65 score of 0 consider hospital assessment for all other patients, particularly those with a CRB65 score of 2 or more.Stratify patients presenting with community-acquired pneumonia into those with low-, moderate- or high-severity disease. The grade of severity will usually correspond to the risk of death.subhead:CRB65 score for mortality risk assessment in primary careCRB65 score is calculated by giving 1 point for each of the following prognostic features: confusion (abbreviated Mental Test score 8 or less, or new disorientation in person, place or time; for guidance on delirium, see what NICE says on delirium) raised respiratory rate (30 breaths per minute or more) low blood pressure (diastolic 60 mmHg or less, or systolic less than 90 mmHg) age 65 years or more.Patients are stratified for risk of death as follows:  0: low risk (less than 1% mortality risk) 1 or 2: intermediate risk (1\u201310% mortality risk) 3 or 4: high risk (more than 10% mortality risk). Score information from defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study (Lim WS, van der Eerden MM, Laing R, et al. 2003).Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.1Mortality risk assessment in primary care using CRB65 scoreSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191", "drug": {}}}, {"category": "treatment", "id": "t8546", "name": "pharmacological therapy", "draggable": "true", "value": {"name": "pharmacological therapy", "type": "treatment related", "time": "", "intention": "ceftriaxone\nit is used to treat or prevent bacterial infections.", "description": "title:pharmacological therapyhead:Pharmacological therapysubhead:Antibiotic therapyOffer antibiotic therapy as soon as possible after diagnosis, and certainly within 4 hours to all patients with community-acquired pneumonia who are admitted to hospital.Low-severity community-acquired pneumoniaOffer a 5-day course of a single antibiotic to patients with low-severity community-acquired pneumonia.Consider amoxicillin in preference to a macrolide or a tetracycline for patients with low-severity community-acquired pneumonia. Consider a macrolide or a tetracycline for patients who are allergic to penicillin.Consider extending the course of the antibiotic for longer than 5 days as a possible management strategy for patients with low-severity community-acquired pneumonia whose symptoms do not improve as expected after 3 days. Explain to patients with low-severity community-acquired pneumonia treated in the community, and when appropriate their families or carers, that they should seek further medical advice if their symptoms do not begin to improve within 3 days of starting the antibiotic, or earlier if their symptoms are worsening.Do not routinely offer patients with low-severity community-acquired pneumonia: a fluoroquinolone  dual antibiotic therapy.Moderate- and high-severity community-acquired pneumoniaConsider a 7- to 10-day course of antibiotic therapy for patients with moderate- or high-severity community-acquired pneumonia.Consider dual antibiotic therapy with amoxicillin and a macrolide for patients with moderate-severity community-acquired pneumonia.Consider dual antibiotic therapy with a beta-lactamase stable beta-lactam and a macrolide for patients with high-severity community-acquired pneumonia. Available beta-lactamase stable beta-lactams include: co-amoxiclav, cefotaxime, ceftaroline fosamil, ceftriaxone, cefuroxime and piperacillin with tazobactam.subhead:Glucocorticosteroid treatmentDo not routinely offer a glucocorticosteroid to patients with community-acquired pneumonia unless they have other conditions for which glucocorticosteroid treatment is indicated.Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.2Antibiotic therapy for diagnosed low-severity community-acquired pneumonia5Antibiotic therapy within 4 hours in hospitalSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191", "drug": {"cefotaxime": "DB00493", "cefuroxime": "DB01112", "amoxicillin": "DB01211", "ceftriaxone": "DB01212"}}}, {"category": "treatment", "id": "t8555", "name": "management of hospital acquired pneumonia", "draggable": "true", "value": {"name": "management of hospital acquired pneumonia", "type": "treatment related", "time": "", "intention": "carbon dioxide\n", "description": "title:management of hospital-acquired pneumoniahead:Management of hospital-acquired pneumoniasubhead:Antibiotic therapyOffer antibiotic therapy as soon as possible after diagnosis, and certainly within 4 hours, to patients with hospital-acquired pneumonia.Choose antibiotic therapy in accordance with local hospital policy (which should take into account knowledge of local microbial pathogens) and clinical circumstances for patients with hospital-acquired pneumonia.Consider a 5- to 10-day course of antibiotic therapy for patients with hospital-acquired pneumonia.NICE has published evidence summaries on: antimicrobial prescribing: Ceftazidime/avibactam hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin.See what NICE says on acutely ill patients in hospital and prevention and control of healthcare-associated infections.Severe acute respiratory failureNICE has published interventional procedures guidance on the following procedures with special arrangements for consent, audit and clinical governance: extracorporeal membrane carbon dioxide removal for acute respiratory failure extracorporeal membrane oxygenation for severe acute respiratory failure in adults.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191", "drug": {}}}, {"category": "treatment", "id": "t8557", "name": "community acquired pneumonia", "draggable": "true", "value": {"name": "community acquired pneumonia", "type": "treatment related", "time": "", "intention": "", "description": "title:community-acquired pneumonia", "drug": {}}}, {"category": "treatment", "id": "t8543", "name": "microbiological tests", "draggable": "true", "value": {"name": "microbiological tests", "type": "treatment related", "time": "", "intention": "antifungal\nthis medicine is used to treat vaginal yeast infections.", "description": "title:microbiological testshead:Microbiological testsDo not routinely offer microbiological tests to patients with low-severity community-acquired pneumonia.For patients with moderate- or high-severity community-acquired pneumonia: take blood and sputum cultures and consider pneumococcal and legionella urinary antigen tests.subhead:Tests for rapidly identifying bloodstream bacteria and fungiThe following recommendations are from NICE diagnostics guidance on tests for rapidly identifying bloodstream bacteria and fungi (LightCycler SeptiFast Test MGRADE, SepsiTest and IRIDICA BAC BSI assay).There is currently insufficient evidence to recommend the routine adoption in the NHS of the LightCycler SeptiFast Test MGRADE, SepsiTest and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi. The tests show promise and further research to provide robust evidence is encouraged, particularly to demonstrate the value of using the test results in clinical decision-making (see sections\u00a05.18 to\u00a05.22 of NICE diagnostics guidance 20).NICE has published a medtech innovation briefing on Fungitell for antifungal treatment stratification.subhead:Procalcitonin testing for diagnosing and monitoring sepsisThe following recommendations are from NICE diagnostics guidance on procalcitonin testing for diagnosing and monitoring sepsis.The procalcitonin tests (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay or VIDAS BRAHMS PCT assay) show promise but there is currently insufficient evidence to recommend their routine adoption in the NHS. Further research on procalcitonin tests is recommended for guiding decisions to: stop antibiotic treatment in people with confirmed or highly suspected sepsis in the intensive care unit or start and stop antibiotic treatment in people with suspected bacterial infection presenting to the emergency department.Centres currently using procalcitonin tests to guide these decisions are encouraged to participate in research and data collection (see section 6.25 of NICE diagnostics guidance 18).See what NICE says on sepsis.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191DG20DG18", "drug": {"antifungal": "DB01110"}}}, {"category": "treatment", "id": "t8548", "name": "adult admitted to hospital", "draggable": "true", "value": {"name": "adult admitted to hospital", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:adult admitted to hospital", "drug": {}}}, {"category": "treatment", "id": "t8547", "name": "adult not admitted to hospital", "draggable": "true", "value": {"name": "adult not admitted to hospital", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:adult not admitted to hospital", "drug": {}}}, {"category": "treatment", "id": "t8558", "name": "assessment", "draggable": "true", "value": {"name": "assessment", "type": "treatment related", "time": "", "intention": "", "description": "title:assessment", "drug": {}}}, {"category": "treatment", "id": "t8544", "name": "management", "draggable": "true", "value": {"name": "management", "type": "treatment related", "time": "", "intention": "", "description": "title:management", "drug": {}}}, {"category": "treatment", "id": "t8549", "name": "monitoring in hospital", "draggable": "true", "value": {"name": "monitoring in hospital", "type": "treatment related", "time": "", "intention": "carbon dioxide\n", "description": "title:monitoring in hospitalhead:Monitoring in hospitalConsider measuring a baseline C-reactive protein concentration in patients with community-acquired pneumonia on admission to hospital, and repeat the test if clinical progress is uncertain after 48 to 72 hours.subhead:Severe acute respiratory failureNICE has published interventional procedures guidance on the following procedures with special arrangements for consent, audit and clinical governance: extracorporeal membrane carbon dioxide removal for acute respiratory failure extracorporeal membrane oxygenation for severe acute respiratory failure in adults.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191", "drug": {}}}, {"category": "treatment", "id": "t8552", "name": "acutely ill patients in hospital", "draggable": "true", "value": {"name": "acutely ill patients in hospital", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:acutely ill patients in hospital", "drug": {}}}, {"category": "treatment", "id": "t8551", "name": "patient information", "draggable": "true", "value": {"name": "patient information", "type": "treatment related", "time": "", "intention": "", "description": "title:patient informationhead:Patient informationExplain to patients with community-acquired pneumonia that after starting treatment their symptoms should steadily improve, although the rate of improvement will vary with the severity of the pneumonia, and most people can expect that by: 1 week: fever should have resolved 4 weeks: chest pain and sputum production should have substantially reduced 6 weeks: cough and breathlessness should have substantially reduced  3 months: most symptoms should have resolved but fatigue may still be present  6 months: most people will feel back to normal. Advise patients with community-acquired pneumonia to consult their healthcare professional if they feel that their condition is deteriorating or not improving as expected.NICE has written information for the public on pneumonia. SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191", "drug": {}}}, {"category": "treatment", "id": "t8559", "name": "management", "draggable": "true", "value": {"name": "management", "type": "treatment related", "time": "", "intention": "", "description": "title:management", "drug": {}}}, {"category": "treatment", "id": "t8550", "name": "safe discharge from hospital", "draggable": "true", "value": {"name": "safe discharge from hospital", "type": "treatment related", "time": "", "intention": "", "description": "title:safe discharge from hospitalhead:Safe discharge from hospitalDo not routinely discharge patients with community-acquired pneumonia if in the past 24 hours they have had 2 or more of the following findings: temperature higher than 37.5\u00b0C  respiratory rate 24 breaths per minute or more heart rate over 100 beats per minute  systolic blood pressure 90 mmHg or less oxygen saturation under 90% on room air abnormal mental status inability to eat and drink without assistance.Consider delaying discharge for patients with community-acquired pneumonia if their temperature is higher than 37.5\u00b0C.Also see discharge vulnerable people from health or social care settings to a warm home in excess winter deaths and illnesses associated with cold homes.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG191", "drug": {}}}, {"category": "drug", "id": "d140", "name": "cefotaxime", "draggable": "true", "value": {"name": "cefotaxime", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d145", "name": "cefuroxime", "draggable": "true", "value": {"name": "cefuroxime", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d142", "name": "ceftaroline fosamil", "draggable": "true", "value": {"name": "ceftaroline fosamil", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d37", "name": "amoxicillin", "draggable": "true", "value": {"name": "amoxicillin", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d144", "name": "ceftriaxone", "draggable": "true", "value": {"name": "ceftriaxone", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d130", "name": "carbon dioxide", "draggable": "true", "value": {"name": "carbon dioxide", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d46", "name": "antifungal", "draggable": "true", "value": {"name": "antifungal", "time": "None", "period": "None", "dosage": "None"}}]}